Literature DB >> 15115382

Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator.

J Joossens1, P Van der Veken, A-M Lambeir, K Augustyns, A Haemers.   

Abstract

In this letter we report the synthesis and biochemical evaluation of selective, irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator (uPA). A diphenyl phosphonate group was introduced on the substratelike peptide Z-d-Ser-Ala-Arg, and modification of the guanidine side chain was investigated. A guanylated benzyl group appeared the most promising side chain modification. A k(app) value in the 10(3) M(-1) s(-1) range for uPA was obtained, together with a selectivity index higher than 240 toward other trypsin-like proteases such as tPA, thrombin, plasmin, and FXa.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115382     DOI: 10.1021/jm0499209

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.

Authors:  Sai MuraliKrishna Pulukuri; Christopher S Gondi; Sajani S Lakka; Aman Jutla; Norman Estes; Meena Gujrati; Jasti S Rao
Journal:  J Biol Chem       Date:  2005-08-26       Impact factor: 5.157

2.  The molecular basis of urokinase inhibition: from the nonempirical analysis of intermolecular interactions to the prediction of binding affinity.

Authors:  Renata Grzywa; Edyta Dyguda-Kazimierowicz; Marcin Sieńczyk; Mikołaj Feliks; W Andrzej Sokalski; Józef Oleksyszyn
Journal:  J Mol Model       Date:  2007-03-20       Impact factor: 1.810

3.  Development and binding characteristics of phosphonate inhibitors of SplA protease from Staphylococcus aureus.

Authors:  Ewa Burchacka; Michal Zdzalik; Justyna-Stec Niemczyk; Katarzyna Pustelny; Grzegorz Popowicz; Benedykt Wladyka; Adam Dubin; Jan Potempa; Marcin Sienczyk; Grzegorz Dubin; Jozef Oleksyszyn
Journal:  Protein Sci       Date:  2013-12-24       Impact factor: 6.725

4.  Disopropyl {[(2S,3S)-2-amino-3-methyl-penta-namido](phen-yl)meth-yl}phosphinate.

Authors:  Hong-Ming Cheng; Han-Wen Zhang; Hua Fang; Zhen Wu; Yu-Fen Zhao
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-12-18

5.  Novel Azido-Iodo Photoaffinity Ligands for the Human Serotonin Transporter Based on the Selective Serotonin Reuptake Inhibitor (S)-Citalopram.

Authors:  Vivek Kumar; Nageswari Yarravarapu; David J Lapinsky; Danielle Perley; Bruce Felts; Michael J Tomlinson; Roxanne A Vaughan; L Keith Henry; John R Lever; Amy Hauck Newman
Journal:  J Med Chem       Date:  2015-07-08       Impact factor: 7.446

6.  De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives.

Authors:  Christopher Heim; Dimanthi Pliatsika; Farnoush Mousavizadeh; Kerstin Bär; Birte Hernandez Alvarez; Athanassios Giannis; Marcus D Hartmann
Journal:  J Med Chem       Date:  2019-07-12       Impact factor: 7.446

Review 7.  Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors.

Authors:  Peng Xu; Peter A Andreasen; Mingdong Huang
Journal:  Int J Biol Sci       Date:  2017-09-21       Impact factor: 6.580

8.  Phosphonate inhibitors of West Nile virus NS2B/NS3 protease.

Authors:  Marcin Skoreński; Aleksandra Milewska; Krzysztof Pyrć; Marcin Sieńczyk; Józef Oleksyszyn
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

Review 9.  Therapeutics targeting the fibrinolytic system.

Authors:  Haili Lin; Luning Xu; Shujuan Yu; Wanjin Hong; Mingdong Huang; Peng Xu
Journal:  Exp Mol Med       Date:  2020-03-09       Impact factor: 8.718

10.  A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation.

Authors:  Cedric Joossen; Adrienn Baán; Carlos Moreno-Cinos; Jurgen Joossens; Nathalie Cools; Ellen Lanckacker; Lieve Moons; Kim Lemmens; Anne-Marie Lambeir; Erik Fransen; Peter Delputte; Guy Caljon; Pieter Van Der Veken; Louis Maes; Ingrid De Meester; Filip Kiekens; Koen Augustyns; Paul Cos
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.